Search hospitals > Texas > Fort Worth

Texas Oncology-Fort Worth Cancer Center

Claim this profile
Fort Worth, Texas 76104
Global Leader in Ovarian Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Cancer
Conducts research for Pancreatic Cancer
98 reported clinical trials
5 medical researchers
Photo of Texas Oncology-Fort Worth Cancer Center in Fort WorthPhoto of Texas Oncology-Fort Worth Cancer Center in Fort WorthPhoto of Texas Oncology-Fort Worth Cancer Center in Fort Worth

Summary

Texas Oncology-Fort Worth Cancer Center is a medical facility located in Fort Worth, Texas. This center is recognized for care of Ovarian Cancer, Breast Cancer, Lung Cancer, Cancer, Pancreatic Cancer and other specialties. Texas Oncology-Fort Worth Cancer Center is involved with conducting 98 clinical trials across 113 conditions. There are 5 research doctors associated with this hospital, such as Noelle Cloven, MD, Stephen Richey, Chi M Pham, and Harris Naina, MD.

Area of expertise

1Ovarian Cancer
Global Leader
Texas Oncology-Fort Worth Cancer Center has run 20 trials for Ovarian Cancer. Some of their research focus areas include:
Stage IV
BRCA1 positive
BRCA2 positive
2Breast Cancer
Global Leader
Texas Oncology-Fort Worth Cancer Center has run 18 trials for Breast Cancer. Some of their research focus areas include:
HER2 negative
Stage IV
ER positive

Top PIs

Clinical Trials running at Texas Oncology-Fort Worth Cancer Center

Endometrial Cancer
Ovarian Cancer
Melanoma
Cervical Cancer
Stomach Cancer
Lung Cancer
Relapse
Follicular Lymphoma
Small Cell Lung Cancer
Breast Cancer
Image of trial facility.

Sacituzumab Govitecan

for Endometrial Cancer

The goal of this clinical study is to find out how the study drug, sacituzumab govitecan (SG) works in participants with endometrial cancer who have received prior treatment with platinum-based chemotherapy and immunotherapy, versus the treatment of physician's choice (TPC). The primary objectives of this study are to evaluate the effect of SG compared to TPC on progression-free survival (PFS) as assessed by blinded independent central review (BICR) and overall survival (OS).
Recruiting2 awards Phase 32 criteria
Image of trial facility.

Selinexor Maintenance Therapy

for Endometrial Cancer

The purpose of this study is to evaluate the efficacy and safety of selinexor as a maintenance treatment in patients with p53 wt endometrial carcinoma (EC), who have achieved a partial response (PR) or complete response (CR) (per Response Evaluation Criteria in Solid Tumors version 1.1 \[RECIST v 1.1\]) after completing at least 12 weeks of platinum-based therapy. A total of 276 participants will be enrolled in the study and randomized in a 1:1 ratio to maintenance therapy with either selinexor or placebo.
Recruiting1 award Phase 32 criteria
Image of trial facility.

ACR-368

for Ovarian Cancer

This trial tests a new drug, ACR-368, alone or with a small dose of another drug, gemcitabine, in patients whose cancers don't respond to standard treatments. A special test helps decide which treatment might work best for each patient. Gemcitabine has been used with other drugs for various cancers, including pancreatic, lung, ovarian, and breast cancers.
Recruiting1 award Phase 210 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Texas Oncology-Fort Worth Cancer Center?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security